Purdue Pharma L.P.

Track this case

Case overview

Case Number:

7:19-bk-23649

Court:

New York Southern

Nature of Suit:

Firms

Companies

Government Agencies

Sectors & Industries:

June 12, 2025
McKinsey Says Purdue Ch. 11 Plan Endangers Sackler Claims

McKinsey & Co. has asked a New York bankruptcy judge to reject the disclosure statement for Purdue Pharma's Chapter 11 plan, saying there is ambiguity on how the plan will deal with the consulting firm's possible claims against former owners in the Sackler family.
June 06, 2025
Purdue Seeks To Stretch Ch. 11 Injunction To November

Purdue Pharma has asked a New York bankruptcy judge to extend a litigation injunction in its Chapter 11 until late November or after it secures confirmation of its bankruptcy plan, whichever is earlier, saying the stay is protecting dozens of settlements.
May 22, 2025
Purdue Eyes Fall Confirmation For New Chapter 11 Plan

Attorneys for Purdue Pharma told a New York bankruptcy judge Thursday that the company aims to send its Chapter 11 plan to a vote over the summer with a fall confirmation hearing to conclude the nearly 6-year-old case.
April 14, 2025
Debt Deals On The Rise, Purdue Can Begin Claims Processing

A Texas district court, not a bankruptcy court, will oversee the U.S. trustee's efforts to claw back millions in legal fees paid to Jackson Walker over an undisclosed relationship between an attorney and bankruptcy judge; out-of-court debt deals eclipsed Chapter 11s by a 4-to-1 ratio last year; and drug manufacturer Purdue Pharma can begin processing claims ahead of a Chapter 11 confirmation hearing. This is the week in bankruptcy.
April 10, 2025
Purdue Cleared To Start Ch. 11 Claims Processing Early

A New York bankruptcy judge on Thursday approved Purdue Pharma's request to appoint claims administrators and begin processing the tens of thousands of claims against the drugmaker, reasoning that doing so ahead of plan confirmation would enable the debtor to make faster distributions to creditors.
March 31, 2025
Ex-US Trustee Head Appeals Firing, Purdue Case Extended

The former director of the U.S. Trustee's Office appealed her removal, alleging the government lacked cause and violated due process. Meanwhile, Purdue Pharma secured more time to protect itself and the Sackler family from lawsuits as the company seeks approval for a $7.4 million opioid settlement plan. And FTX told a court it has $11.4 billion ready for creditors but is still reviewing a massive volume of claims before the distribution.
March 28, 2025
Purdue Lawsuit Injunction Extended Ahead Of Plan Hearings

Bankrupt drugmaker Purdue Pharma LP received a further extension of a bar on litigation against the company and its owners in the Sackler family as the debtor pursues a late May approval of a disclosure statement describing a Chapter 11 plan premised on a $7.4 billion settlement of opioid claims.
March 25, 2025
Purdue Mediators Say US Trustee OK With New Releases

The mediators guiding plan negotiations among bankrupt drugmaker Purdue Pharma and its various creditor constituencies said in a Tuesday report that the U.S. Trustee's Office has agreed to release language in the debtor's latest plan after fighting an earlier version all the way to the Supreme Court.
March 24, 2025
Purdue Files New Plan, Forever 21 Hits Ch. 11 For 2nd Time

Purdue Pharma proposed a new bankruptcy plan, under which the Sackler family and the company would pay a total of $7.4 billion to settle opioid-related claims. Meanwhile, Forever 21's U.S. arm filed for Chapter 11 protection in Delaware, securing court approval to close more than 300 stores and planning to exit bankruptcy by June. Plus, a Texas bankruptcy judge rejected an $8 million bid to purchase right-wing conspiracy theory peddler Alex Jones' Infowars, shutting down a request to reopen the asset sale process.
March 19, 2025
Purdue Pharma Files New $7.4B Ch. 11 Plan Settlement

Bankrupt OxyContin maker Purdue Pharma LP filed a new Chapter 11 plan in a New York bankruptcy court, including a $6.5 billion payment from members of the Sackler family who own the company and $900 million from the debtor, that aims to compensate thousands of creditors for damages from opioid sales.

← Previous
1
2
3
4
5
6
7
8
9
…
Next →